Imaging agents for early detection and monitoring of cardiovascular plaque

• US 7,060,251 B1
• Filed: 09/08/1998
• Issued: 06/13/2006
• Est. Priority Date: 09/08/1997
• Status: Expired due to Fees

• Current Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Original Assignee: The General Hospital Corporation (Mass General Brigham, Inc.)
• Inventors: Babich, John W., Elmaleh, David R., Fischman, Alan J.
• Primary Examiner(s): JONES, DAMERON LEVEST
• Application Number:
  US09/530,818
• Time in Patent Office: 2,835 Days
• Field of Search: 424/1.11, 424/1.65, 424/1.69, 424/1.49, 424/1.73, 424/1.81, 424/9.1, 424/1.85, 424/1.89, 424/9.3, 424/9.4, 424/9.5, 424/9.7, 424/9.6, 424/9.8, 206/223, 206/569, 206/570, 534/7, 534 10- 16
• US Class Current: 424/9.4
• CPC Class Codes: A61K 51/088 conjugates with carriers being peptides, polyamino acids or proteins antibodies A61K51/10

Abstract

The invention provides imaging agents comprising a label in association with a plaque specific targeting molecule. Methods for using the imaging agents to diagnose or monitor plaque formation and growth and kits containing the cardiovascular agents or components suitable for production of the imaging agents are also provided.

Claims

1. A cardiovascular imaging agent comprising a radionuclide, said radionuclide being chemically bonded to a targeting moiety comprising a component of a process involved in plaque formation, wherein the targeting moiety is fibrin, thrombin, fibrinogen, factor VIII, or factor IX, wherein said radionuclide is a positron emitting radionuclide selected from the following:

¹⁸F, ⁶⁸Ga, ⁶²Cu, or radioactive isotopes of iodine.

2. The agent of claim 1, wherein said plaque is an atherosclerotic forming plaque.

3. A method of imaging cardiovascular plaque formation in a mammal, comprising administering to the mammal a cardiovascular imaging agent having a radionuclide, said radionuclide being chemically bonded to a targeting moiety comprising a component of a process involved in plaque formation, wherein the targeting moiety is fibrin, thrombin, fibrinogen, factor VIII, or factor IX, wherein said radionuclide is a positron emitting radionuclide selected from the following:

¹⁸F, ⁶⁸Ga, ⁶²Cu, or radioactive isotopes of iodine.

4. The method of claim 3, wherein the method detects a cardiovascular lesion in a mammal, said method comprising the steps of administering to the mammal said imaging agent, detecting the spatial distribution of said agent accumulated in the mammal'"'"'s cardiovascular system, wherein a detected accumulation of said agent in a region which is different from the detected accumulation of said agent in other regions is indicative of a lesion.

5. The method of claim 4, wherein said cardiovascular lesion is an atherosclerotic forming lesion.

6. A kit for cardiovascular imaging, comprising a supply of the imaging agent or a precursor of the imaging agent having a radionuclide, said radionuclide being chemically bonded to a targeting moiety comprising a component of a process involved in plaque formation, wherein the targeting moiety is fibrin, thrombin, fibrinogen, factor VIII, or factor IX, wherein said radionuclide is a positron emitting radionuclide selected from the following:

¹⁸F, ⁶⁸Ga, ⁶²Cu, or radioactive isotopes of iodine.